PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 2025Future Oncology7 citationsOpen Access

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation

View Full Paper
ASAlison M. SchramMFMarc FellousKLKim LeDuke

Key Points

  • Rezapatopting shows promise in targeting tumors with the TP53 Y220C mutation, enhancing treatment options.
  • Participants with advanced solid tumors will be evaluated for safety and efficacy of PC14586 treatment.
  • Phase II clinical trial protocol outlines methods for measuring treatment outcomes in this specific patient group.
  • Findings may enable targeted therapies for advanced metastatic tumors, addressing a pressing need in oncology.

Abstract

NCT04585750 (ClinicalTrials.gov).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schram et al. (2025) studied this question.

synapsesocial.com/papers/68d44a4031b076d99fa538a9https://doi.org/10.1080/14796694.2025.2557176
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of quantitative bias analysis to evaluate single‐arm trials with real‐world data external controls2024 · 10 citations
  2. 2Small molecule induced reactivation of mutant p53 in cancer cells2013 · 236 citations
  3. 3p53: A player in the tumor microenvironment2025 · 17 citations
  4. 4TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data2016 · 752 citations
  5. 5G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer2019 · 69 citations